Ultragenyx Pharmaceutical
RARE
172 hedge funds and large institutions have $2.79B invested in Ultragenyx Pharmaceutical in 2016 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 67 increasing their positions, 56 reducing their positions, and 15 closing their positions.
132% more call options, than puts
Call options by funds: $14.3M | Put options by funds: $6.15M
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
54% more capital invested
Capital invested by funds: $1.81B → $2.79B (+$978M)
20% more repeat investments, than reductions
Existing positions increased: 67 | Existing positions reduced: 56
7% more funds holding
Funds holding: 161 → 172 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
Top Sellers
| 1 |
Wells Fargo
San Francisco,
California
|
-$39.1M |
| 2 |
Millennium Management
New York
|
-$28.8M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$11.5M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$11.2M |
| 5 |
WC
Weatherbie Capital
Boston,
Massachusetts
|
-$6.84M |
RARE Hedge Fund Activity: Q3 2016 in Review
172 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2016, worth a combined $2.79B — up 54% from $1.81B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new RARE positions and 15 closed out — a net gain of 12 holders — while 67 added to existing stakes and 56 trimmed.
The largest buyer was Capital Guardian Trust, opening a new position worth an estimated $31.5M. The largest seller was Wells Fargo, cutting an estimated $39.1M.
- 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2016, up from 161 in Q2 2016.
- Funds reported $2.79B of Ultragenyx Pharmaceutical stock for Q3 2016, up 54% quarter-over-quarter.
- 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of +12 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q3 2016 was Capital Guardian Trust, an estimated $31.5M added.
- The largest Ultragenyx Pharmaceutical seller in Q3 2016 was Wells Fargo, an estimated $39.1M sold.
Based on aggregated 13F filings for Q3 2016.